Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

More documents

Recommendations

Info

REFERENCES Known drug interactions ● Concurrent use of progestins may reduce the efficacy of prostaglandins. ● Concurrent use of other ecbolic agents (e.g. oxytocin) may have additional myotonic effects. MISCELLANEOUS DRUGS Methylergometrine Oral methylergometrine maleate (0.5 mL PO, q.8 h) has been proposed as an adjuvant therapy in cases of moderate uterine hemorrhage, for example after parturition. In women, it displays a uterotonic effect, probably via a stimulation of myometrial α-adrenergic receptors. Its action remains effective for 4–6 h. This drug should not be used with sympathomimetics, ergotamine or dopaminergic drugs. No adverse effect has been observed with the concomitant use of oxytocin. It should not be given during pregnancy. Phenylpropanolamine Phenylpropanolamine, an α-adrenergic compound commonly used to treat urinary incontinence in spayed bitches, has been proved to be effective in cases of retrograde ejaculation in infertile male dogs. The dose is 2 mg/kg q.24 h PO for 5 consecutive days or 3 mg/kg twice daily orally. The onset of action may take several days. Adverse effects may include restlessness, aggressiveness, irritability and hypertension. Aromatase inhibitors Aromatase inhibitors, such as formestane, exert an antiandrogenic effect by inhibiting the conversion of testosterone to estradiol 17β in peripheral tissues. Recently, some of these compounds (4-androsten-4- ol-3,17-dione) have been successfully used experimentally to improve spermatogenic function in oligozoospermic and azoospermic dogs. REFERENCES Axner E 2006 Practical approach to physiology of reproduction in cats. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 56-59 Baan M, Taverne MAM, Kooistra HS, de Gier J, Dieleman SJ, Okkens AC 2005 Induction of parturition in the bitch with the progesteronereceptor blocker aglepristone. Theriogenology 63: 1958-1972 Beaufays F, Onclin K, Lecouls G, Verstegen J 2004 Treatment of retrograde ejaculation in the male dog by phenylpropanolamine: a dose titration study. In: Proceedings of the 4th International Symposium on Canine and Feline Reproduction, August 4-6, São Paulo, Brazil, pp 170-172 Bhatti SFM, Duchateau L, Okkens AC, Van Ham LML, Mol JA, Kooistra HS 2006 Treatment of growth hormone excess in dogs with the progesterone receptor antagonist aglepristone. Theriogenology 66: 797-803 Bogaerts P 2006 Clinical approach to genital and mammary pathologies in cats. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 68-76 Bouchard GF, Gross S, Ganjam VK et al 1993 Estrus induction in the bitch with the synthetic estrogen diethylstilboestrol. J Reprod Fertil 1(suppl 47): 515 Buff S 2004 Luteal insufficiency and abortion. In: Proceedings of the EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), June 4-6, Barcelona, Spain, pp 79-81 Buff S, Fontbonne A, Saint-Dizier M, Guerin P 1998 Induction of estrus with oral administration of cabergoline. In: Proceedings of the 1st EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), May 1-3, Barcelona, Spain, p 314 Corrada Y, Arias D, Rodriguez R, Spaini E, Fava F, Gobello C 2004 Effect of tamoxifen citrate on reproductive parameters of male dogs. Theriogenology 61: 1327-1341 Corrada Y, Hermo G, de la Sota PE, Garcia P, Trigg T, Gobello C 2006 A short term progestin treatment prevents estrous induction by a GnRH agonist implant in anestrous bitches. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, p 278 Davidson AP 2006 When and how caesarean section can be avoided (medical management of labor). In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 93-99 England GCW 1997 Effect of progestins and androgens upon spermatogenesis and steroidogenesis in dogs. J Reprod Fertil 51(suppl): 123-138 England GCW, Hewitt DA 1999 Mechanism and regulation of follicular growth. In: Proceedings of the EVSSAR (European Veterinary Society for Small Animal Reproduction) Annual Symposium, September 22nd , Lyon, France, p 51 England GCW, Russo M 2004 Treatment of spontaneous pyometra in the bitch with a combination of cabergoline and prostaglandin. In: Proceedings of the 4th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), June 4-6, Barcelona, Spain, pp 277-278 Feldman EC, Nelson RW 1989 Diagnosis and treatment alternatives for pyometra in dogs and cats. In: Kirk RW (ed.) Current veterinary therapy X. WB Saunders, Philadelphia, PA, pp 1305-1310 Fieni F 2006 Antiprogestins and obstetrics. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 123-128 Fieni F, Fuhrer M, Tainturier D, Bruyas JF, Dridi S 1989 Use of cloprostenol for pregnancy termination in dogs. J Reprod Fertil 39(suppl): 332-333 Fieni F, Tainturier D, Bruyas JF et al 1996 Etude clinique d’une antihormone pour provoquer l’avortement chez la chienne. Recueil Med Vet 172(7/8): 359-367 Fieni F, Verstegen J, Heraud D, Onclin K 1999 Physiologie de la prolactine, pharmacologiedes antiprolactiniques et applications chez la chienne. Prat Med Chirurg Anim Comp 34: 187-199 Fieni F, Bruyas JF, Battut I, Tainturier D 2001 Clinical use of antiprogestins in the bitch. In: Concannon PW, England G, Verstegen J (eds) Recent advances in small animal reproduction. IVIS, NewYork 543
CHAPTER 23 DRUGS AND REPRODUCTION Fieni F, Marnet PG, Martal J et al 2001 Comparison of two protocols with a progesterone antagonist aglepristone (RU534) to induce parturition in bitches. J Reprod Fertil 57(suppl): 237-242 Galac S, Kooistra HS, Butinar J, Bevers MM, Dieleman SJ, Voorhout G, Okkens AC. Termination of mid-gestation pregnancy in bitches with aglepristone, a progesterone receptor antagonist. Theriogenology. 2000 Mar 1; 53(4): 941-50 Gobello C 2006 Dopamine agonists, anti-progestins, anti-androgens, long-term release GnRH agonist and anti-oestrogens in canine reproduction: a review. Theriogenology 66: 1560-1567 Gobello C, Castex G, Broglia G, Corrada Y 2003 Coat colour changes associated with cabergoline administration in bitches. J Small Anim Pract 44(8): 352-354 Gobello C, Castex G, Klima L Rodriguez R, Corrada Y 2003 A study of two protocols combining aglepristone and cloprostenol to treat open cervix pyometra in the bitch. Theriogenology 60: 901-908 Gorlinger S, Kooistra HS, van der Broek A, Okkens AC 2002 Treatment of fibroadenomatous hyperplasia in cats with aglepristone. J Vet Intern Med 16(6): 710-713 Hori T, Akikawa T, Kawakami E, Tutsui T 2002 Effects of administration of prostaglandin F2a - analogue fenprostalene on canine corpus luteum and subsequent recurrence of estrus and fecundity. J Vet Med Sci 64(9): 807-811 Iguer-Ouada M, Verstegen JP 1997 Effect of finasteride (Proscar, MSD) on seminal composition, prostate function and fertility in male dogs. J Reprod Fertil 51(suppl): 139-149 Inaba T, Tani H, Gonda M et al 1998 Induction of fertile estrus in bitches using a sustained-release formulation of a GnRH agonist (leuprolide acetate). Theriogenology 49: 975-982 Johnston SD, Root-Kustritz MV, Olson PN 2001 Canine and feline theriogenology. WB Saunders, Philadelphia, PA Kawakami E, Hirano T, Hori T, Tsutsui T 2004 Improvement in spermatogenic function after subcutaneous implantation of a capsule containing an aromatase inhibitor in four oligozoospermic dogs and one azoospermic dog with high plasma estradiol-17β levels. Theriogenology 62: 165-178 Kützler MA 2005 Induction and synchronisation of estrus in dogs. Theriogenology 64: 766-775 Kützler MA, Wheeler R, Lamb SV, Volkmann DH 2002 Deslorelin implant administration beneath the vulvar mucosa for the induction of synchronous estrus in bitches. In Proceedings of the 3rd EVSSAR congress (European Veterinary Society for Small Animal Reproduction). 2002, Liège, Belgium, 96 Kützler M, Stang B, Waldvogel R, Holthofer P 2006 Administration of a single or multiple doses of injectable long-acting deslorelin (GnRH analogue) does not induce oestrus in bitches. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, p 280 Lange K, Günzel-Apel AR, Hoppen HO, Mischke R, Nolte I 1997 Effects of low doses of prostaglandin F2a during the early luteal phase before and after implantation in beagle bitches. J Reprod Fertil 51(suppl): 251-257 Lennoz-Roland M 2006 Practical uses of aglepristone: review of a recent expert meeting. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 152-159 Ludwig C, Desmoulins PO, Flocxhay-Sigognault A, Driancourt MA, Hoffmann B 2006 Treatment with a subcutaneous GnRH agonistcontaining implant down-regulates the hypothalamo-pituitarygonadal axis of male dogs. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, p 317 Mimouni P, Noullet M, Albouy M, Sanquer A 2006 Treatment of benign prostatic hyperplasia with Osaterone acetate tablets: a study in breeding dogs. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, p 303 Morgan RV 1988 Handbook of small animal practice. Churchill Livingstone, New York Okkens AC, Kooistra HS, Diele SJ, Bevers MM 1997 Dopamine agonist effects as opposed to prolactin concentrations in plasma as the influencing factor on the duration of anoestrus in bitches. J Reprod Fertil 51(suppl): 55-58 Olsen PN, Bowen RA, Husted PW, Nett TM 1986 Terminating canine and feline pregnancies. In: Kirk RW (ed.) Current veterinary therapy IX. WB Saunders, Philadelphia, PA, pp 1236-1240 Onclin K, Verstegen JP 1997 Termination of pregnancy in cats using a combination of cabergoline, a new dopamine agonist and a synthetic PGF 2a cloprostanol. J Reprod Fertil 51(suppl): 259-263 Plumb DC 2000 Veterinary drug handbook, 3rd edn. Iowa State University Press, Ames, IA, pp 194-195 Ponglowhapan S, Lohachit C, Swangchanuthai T, Trigg TE 2002 The effect of the GnRH agonist deslorelin on prostatic volume in dogs. In: Proceedings of the 3rd EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), Liège, Belgium, p 150 Reynaud K, Fontbonne A, Marseloo N et al 2005 In vivo meiotic resumption, fertilization and early embryonic development in the bitch. Reproduction 130(2): 193-201 Romagnoli S 2004 Retrograde ejaculation. In: Proceedings of the 4th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), June 4-6, Barcelona, Spain, pp 233-239 Romagnoli S 2006 Deslorelin in small animal andrology. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, pp 204-207 Romagnoli S, Concannon PW 2003 Clinical use of progestins in bitches and queens: a review. In: Concannon PW, England G, Verstegen J (eds) Recent advances in small animal reproduction. IVIS, New York Romagnoli S, Frumento P, Abramo F 2002 Induction of ovulation in the estrous queen with GnRH: a clinical study. In Proceedings of the 3rd EVSSAR congress (European Veterinary Society for Small Animal Reproduction). 2002, Liège, Belgium, 160-161 Romagnoli S, Fieni F, Prats A, Gardey L, Vannozzi I, Rota A 2006 Treatment of canine open-cervix and closed-cervix pyometra with combined administration of aglepristone and misoprostol. In: Proceedings of the 5th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), April 7-9, Budapest, Hungary, p 287 Root-Kustritz MV 2001 Use of supplemental progesterone in management of canine pregnancy. In: Concannon PW, England G, Verstegen J (eds) Recent advances in small animal reproduction. IVIS, New York Rubion S, Desmoulins PO, Rivière-Godet E et al 2006 Treatment with a subcutaneous GnRH agonist containing controlled device reversibly prevents puberty in bitches. Theriogenology 66: 1651-1654 Salo F, Illas J, Arus J, Vinaixa F 2004 Use of tamoxiphen for treatment of two cases of benign prostate hyperplasia with prostatic cysts. In: Proceedings of the 4th EVSSAR Congress (European Veterinary Society for Small Animal Reproduction), June 4–6, Barcelona, Spain, p 301 Shille VM, Olsen PN 1989 Dynamic testing in reproductive endocrinology. In: Kirk RW (ed.) Current veterinary therapy X. WB Saunders, Philadelphia, PA, pp 1282-1288 Sirinarumitr K, Sirinarumitr T, Johnston SD, Sarkar DK, Kustritz MV 2002 Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy. Am J Vet Res 63(4): 495-498 Sutton DJ, Greary MR, Bergman JGHE 1997 The prevention of pregnancy in bitches following unwanted mating: a clinical trial using low dose oestradiol benzoate. J Reprod Fertil 51(suppl): 239-243 Trigg T 2004 Advances in use of the GnRH agonist deslorelin in control of reproduction. In: Proceedings of the 5th International Symposium on Canine and Feline Reproduction, August 4–6, São Paulo, Brazil, pp 49-51 544
Page 1 and 2:
An imprint of Elsevier Limited © E
Page 3 and 4:
CONTRIBUTORS Matthias J Kleinz Depa
Page 5 and 6:
Dedication To Tom, Rosalind and Jim
Page 7 and 8:
CHAPTER 1 PRINCIPLES OF CLINICAL PH
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
CHAPTER 2 CLINICAL PHARMACOKINETICS
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
CHAPTER 3 ADVERSE DRUG REACTIONS Un
Page 49 and 50:
CHAPTER 3 ADVERSE DRUG REACTIONS to
Page 51 and 52:
CHAPTER 3 ADVERSE DRUG REACTIONS
Page 53 and 54:
CHAPTER 3 ADVERSE DRUG REACTIONS He
Page 55 and 56:
CHAPTER 3 ADVERSE DRUG REACTIONS an
Page 57 and 58:
CHAPTER 3 ADVERSE DRUG REACTIONS wh
Page 59 and 60:
CHAPTER 3 ADVERSE DRUG REACTIONS at
Page 61 and 62:
CHAPTER 3 ADVERSE DRUG REACTIONS Ps
Page 63 and 64:
CHAPTER 3 ADVERSE DRUG REACTIONS su
Page 65 and 66:
CHAPTER 4 THE PHARMACOLOGY OF THE A
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
CHAPTER 5 ANESTHETIC AGENTS However
Page 91 and 92:
CHAPTER 5 ANESTHETIC AGENTS The gre
Page 93 and 94:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 95 and 96:
CHAPTER 5 ANESTHETIC AGENTS doses.
Page 97 and 98:
CHAPTER 5 ANESTHETIC AGENTS ● hig
Page 99 and 100:
CHAPTER 5 ANESTHETIC AGENTS concent
Page 101 and 102:
CHAPTER 5 ANESTHETIC AGENTS X R 3 C
Page 103 and 104:
CHAPTER 5 ANESTHETIC AGENTS Emergen
Page 105 and 106:
CHAPTER 5 ANESTHETIC AGENTS inhalat
Page 107 and 108:
CHAPTER 5 ANESTHETIC AGENTS and enh
Page 109 and 110:
CHAPTER 5 ANESTHETIC AGENTS ● Exc
Page 111 and 112:
CHAPTER 5 ANESTHETIC AGENTS Pharmac
Page 113 and 114:
CHAPTER 5 ANESTHETIC AGENTS Central
Page 115 and 116:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 117 and 118:
CHAPTER 5 ANESTHETIC AGENTS FURTHER
Page 119 and 120:
CHAPTER 6 SEDATIVES ● noradrenali
Page 121 and 122:
CHAPTER 6 SEDATIVES treatment, with
Page 123 and 124:
CHAPTER 6 SEDATIVES Benzodiazepines
Page 125 and 126:
CHAPTER 6 SEDATIVES It is not misci
Page 127 and 128:
CHAPTER 6 SEDATIVES respectively. H
Page 129 and 130:
CHAPTER 6 SEDATIVES Table 6.1 Sugge
Page 131 and 132:
7 Behavior-modifying drugs Kersti S
Page 133 and 134:
CHAPTER 7 BEHAVIOR-MODIFYING DRUGS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
8 Antibacterial drugs Jill E Maddis
Page 155 and 156:
CHAPTER 8 ANTIBACTERIAL DRUGS phary
Page 157 and 158:
CHAPTER 8 ANTIBACTERIAL DRUGS dose
Page 159 and 160:
CHAPTER 8 ANTIBACTERIAL DRUGS Table
Page 161 and 162:
Page 163 and 164:
CHAPTER 8 ANTIBACTERIAL DRUGS Bacte
Page 165 and 166:
CHAPTER 8 ANTIBACTERIAL DRUGS lacta
Page 167 and 168:
CHAPTER 8 ANTIBACTERIAL DRUGS Antis
Page 169 and 170:
CHAPTER 8 ANTIBACTERIAL DRUGS intri
Page 171 and 172:
Page 173 and 174:
CHAPTER 8 ANTIBACTERIAL DRUGS inter
Page 175 and 176:
CHAPTER 8 ANTIBACTERIAL DRUGS Teico
Page 177 and 178:
CHAPTER 8 ANTIBACTERIAL DRUGS less
Page 179 and 180:
CHAPTER 8 ANTIBACTERIAL DRUGS Diffe
Page 181 and 182:
CHAPTER 8 ANTIBACTERIAL DRUGS forms
Page 183 and 184:
CHAPTER 8 ANTIBACTERIAL DRUGS ● I
Page 185 and 186:
CHAPTER 8 ANTIBACTERIAL DRUGS In an
Page 187 and 188:
CHAPTER 8 ANTIBACTERIAL DRUGS ● R
Page 189 and 190:
CHAPTER 8 ANTIBACTERIAL DRUGS RIFAM
Page 191 and 192:
9 Systemic antifungal therapy Josep
Page 193 and 194:
CHAPTER 9 SYSTEMIC ANTIFUNGAL THERA
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 Antiparasitic drugs Stephen W Pa
Page 205 and 206:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 207 and 208:
CHAPTER 10 ANTIPARASITIC DRUGS Tabl
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
CHAPTER 10 ANTIPARASITIC DRUGS leva
Page 217 and 218:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 219 and 220:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 221 and 222:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 223 and 224:
CHAPTER 10 ANTIPARASITIC DRUGS Form
Page 225 and 226:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 227 and 228:
Page 229 and 230:
CHAPTER 10 ANTIPARASITIC DRUGS prod
Page 231 and 232:
CHAPTER 10 ANTIPARASITIC DRUGS Lufe
Page 233 and 234:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 235 and 236:
CHAPTER 10 ANTIPARASITIC DRUGS 62.5
Page 237 and 238:
CHAPTER 10 ANTIPARASITIC DRUGS incr
Page 239 and 240:
CHAPTER 10 ANTIPARASITIC DRUGS rest
Page 241 and 242:
CHAPTER 10 ANTIPARASITIC DRUGS The
Page 243 and 244:
CHAPTER 10 ANTIPARASITIC DRUGS 238
Page 245 and 246:
Page 247 and 248:
CHAPTER 10 ANTIPARASITIC DRUGS In a
Page 249 and 250:
CHAPTER 10 ANTIPARASITIC DRUGS func
Page 251 and 252:
CHAPTER 10 ANTIPARASITIC DRUGS Para
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
CHAPTER 11 GLUCOCORTICOSTEROIDS AND
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
12 Immunomodulatory therapy Michael
Page 277 and 278:
CHAPTER 12 IMMUNOMODULATORY THERAPY
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
CHAPTER 13 NONSTEROIDAL ANTI-INFLAM
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
CHAPTER 14 OPIOID ANALGESICS inflam
Page 317 and 318:
A Agonist opioid (morphine) B Parti
Page 319 and 320:
CHAPTER 14 OPIOID ANALGESICS admini
Page 321 and 322:
CHAPTER 14 OPIOID ANALGESICS may ac
Page 323 and 324:
CHAPTER 14 OPIOID ANALGESICS Small
Page 325 and 326:
CHAPTER 14 OPIOID ANALGESICS Clinic
Page 327 and 328:
CHAPTER 14 OPIOID ANALGESICS Contra
Page 329 and 330:
CHAPTER 14 OPIOID ANALGESICS respon
Page 331 and 332:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 333 and 334:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 335 and 336:
15 Cancer chemotherapy Jane M Dobso
Page 337 and 338:
CHAPTER 15 CANCER CHEMOTHERAPY to m
Page 339 and 340:
CHAPTER 15 CANCER CHEMOTHERAPY curr
Page 341 and 342:
CHAPTER 15 CANCER CHEMOTHERAPY Tabl
Page 343 and 344:
CHAPTER 15 CANCER CHEMOTHERAPY Clin
Page 345 and 346:
CHAPTER 15 CANCER CHEMOTHERAPY sion
Page 347 and 348:
CHAPTER 15 CANCER CHEMOTHERAPY In t
Page 349 and 350:
CHAPTER 15 CANCER CHEMOTHERAPY afte
Page 351 and 352:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 353 and 354:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 355 and 356:
CHAPTER 15 CANCER CHEMOTHERAPY conc
Page 357 and 358:
CHAPTER 15 CANCER CHEMOTHERAPY ●
Page 359 and 360:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 361 and 362:
CHAPTER 15 CANCER CHEMOTHERAPY in t
Page 363 and 364:
CHAPTER 15 CANCER CHEMOTHERAPY Adve
Page 365 and 366:
CHAPTER 15 CANCER CHEMOTHERAPY best
Page 367 and 368:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 369 and 370:
CHAPTER 15 CANCER CHEMOTHERAPY baso
Page 371 and 372:
CHAPTER 15 CANCER CHEMOTHERAPY D-MA
Page 373 and 374:
CHAPTER 16 ANTICONVULSANT DRUGS sei
Page 375 and 376:
CHAPTER 16 ANTICONVULSANT DRUGS bit
Page 377 and 378:
CHAPTER 16 ANTICONVULSANT DRUGS Kno
Page 379 and 380:
CHAPTER 16 ANTICONVULSANT DRUGS Mec
Page 381 and 382:
CHAPTER 16 ANTICONVULSANT DRUGS rap
Page 383 and 384:
CHAPTER 16 ANTICONVULSANT DRUGS exc
Page 385 and 386:
17 Drugs used in the management of
Page 387 and 388:
CHAPTER 17 DRUGS USED IN THE MANAGE
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
18 Drugs used in the management of
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
CHAPTER 19 GASTROINTESTINAL DRUGS C
Page 477 and 478:
CHAPTER 19 GASTROINTESTINAL DRUGS r
Page 479 and 480:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 481 and 482:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 483 and 484:
CHAPTER 19 GASTROINTESTINAL DRUGS w
Page 485 and 486:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 487 and 488:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 489 and 490:
CHAPTER 19 GASTROINTESTINAL DRUGS i
Page 491 and 492:
CHAPTER 19 GASTROINTESTINAL DRUGS L
Page 493 and 494:
CHAPTER 19 GASTROINTESTINAL DRUGS P
Page 495 and 496:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 497 and 498: CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 499 and 500: CHAPTER 19 GASTROINTESTINAL DRUGS Z
Page 501 and 502: CHAPTER 19 GASTROINTESTINAL DRUGS
Page 503 and 504: 20 Drugs used in the management of
Page 505 and 506: CHAPTER 20 DRUGS USED IN THE MANAGE
Page 515 and 516: CHAPTER 21 DRUGS USED IN THE TREATM
Page 533 and 534: 23 Drugs and reproduction Philip G
Page 535 and 536: CHAPTER 23 DRUGS AND REPRODUCTION I
Page 537 and 538: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 539 and 540: CHAPTER 23 DRUGS AND REPRODUCTION C
Page 541 and 542: CHAPTER 23 DRUGS AND REPRODUCTION M
Page 543 and 544: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 545 and 546: CHAPTER 23 DRUGS AND REPRODUCTION n
Page 547: CHAPTER 23 DRUGS AND REPRODUCTION E
Page 551 and 552: 24 Topical dermatological therapy R
Page 553 and 554: CHAPTER 24 TOPICAL DERMATOLOGICAL T
Page 563 and 564: CHAPTER 25 OCULAR CLINICAL PHARMACO
Page 579 and 580: Index A α-adrenergic receptors 70,
Page 581 and 582: INDEX Antiplatelet drugs 456-457 pi
Page 583 and 584: INDEX Ceftazidime 168 Ceftiofur 166
Page 585 and 586: INDEX Drug receptors 4-8 Drug-drug
Page 587 and 588: INDEX Hepatic excretion 33 Hepatic
Page 589 and 590: INDEX Metabolism dogs vs cats 47 an
Page 591 and 592: INDEX Pentazocine 319, 327 Pentobar
Page 593 and 594: INDEX Semicarbazone 230 Septic arth
show all

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

Create successful ePaper yourself

Delete template?

Save as template?